Device Trial Radar · NCT01874392
Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp
Last checked: Nov 20, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Oct 2012
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Sansum Diabetes Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Juvenile Diabetes Research Foundation
- First posted
- Jun 11, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a feasibility study to assess the performance of an Artificial Pancreas (AP) device using the Artificial Pancreas System (APS©) platform for subjects with type 1 diabetes using rapid-acting insulin as well as preprandial inhaled insulin (Technosphere® Insulin Inhalation System by MannKind Corporation). The goal of this proposed study is to explore the feasibility of using multiple insulin delivery routes in order to mimic the physiology of both first- and second-phase insulin secretion. The intent is to exploit the rapid action achieved by inhaled insulin to compensate for part of the meals and utilize the conventional subcutaneous route for management of basal insulin and as second-phase meal-related insulin.
Conditions
- Type 1 Diabetes Mellitus
Interventions
Investigational inhaled insulin (Technosphere)Drug
by MannKind Corp. IND 61,729
Artificial Pancreas (AP) device (APS©)Device
Device includes: * OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp. * Dexcom® G4® CGM System (CGM) from Dexcom® Corp * Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.Time frame: 5 hours
- Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.Time frame: 25-28 hours
- Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) SettingTime frame: 30 minutes
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sansum Diabetes Research Institute
Santa Barbara, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.